Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2521 to 2535 of 9026 results

  1. Surgical mesh for treatment of non-primary ventral hernias

    In development Reference number: GID-HTG10165 Expected publication date: TBC

    HealthTech guidance
    In development

  2. NICE Funding Variation Request Consultation: methods / process manual consultation

    We are listening to your views on this NICE process and methods. Comments close 19 June 2026.

    In consultation

  3. Nirogacestat for treating desmoid tumours [ID6453]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 1 June 2026.

    Technology appraisal guidance
    In consultation

  4. Nirogacestat for treating desmoid tumours [ID6453]

    In development Reference number: GID-TA11559 Expected publication date:  05 August 2026

    Technology appraisal guidance
    In development

  5. Satralizumab for treating thyroid eye disease [ID6648]

    Awaiting development Reference number: GID-TA11860 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Camizestrant for treating oestrogen receptor-positive HER2-negative early breast cancer at risk of recurrence after 2 to 5 years of adjuvant endocrine treatment [GID-TA11987]

    Awaiting development Reference number: GID-TA11987 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Surovatamig for treating relapsed or refractory follicular lymphoma after 2 or more treatment lines [GID-TA11976]

    Awaiting development Reference number: GID-TA11976 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Olomorasib with pembrolizumab for untreated KRAS G12C mutation- and PD-L1-positive unresectable advanced non-small-cell lung cancer [GID-TA12003]

    Awaiting development Reference number: GID-TA12003 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Olomorasib in combination for untreated KRAS G12C mutation-positive unresectable advanced non-squamous non-small-cell lung cancer [GID-TA12001]

    Awaiting development Reference number: GID-TA12001 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Headaches (update): Prophylactic treatment of migraine - Candesartan

    In development Reference number: GID-NG10472 Expected publication date: TBC

    NICE guideline
    In development

  11. Olezarsen for treating severe hypertriglyceridaemia [GID-TA12016]

    Awaiting development Reference number: GID-TA12016 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Amlitelimab for treating moderate to severe atopic dermatitis in people 12 years and over [GID-TA12005]

    Awaiting development Reference number: GID-TA12005 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Grazax for treating allergic rhinitis and conjunctivitis caused by grass pollen in people 5 years and over [GID-TA12010]

    Awaiting development Reference number: GID-TA12010 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Obsessive-compulsive disorder and body dysmorphic disorder

    In development Reference number: GID-QS10200 Expected publication date:  16 February 2027

    Quality standard
    In development

  15. Emactuzumab for treating localised or diffuse tenosynovial giant cell tumours when surgery is unsuitable [GID-TA12000]

    Awaiting development Reference number: GID-TA12000 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development